Over 3 million SARS-CoV2 genome sequences shared through the GSAID This link will open in a new window database.
GSK, Johnson & Johnson, and MSD partner with Gavi and the International Federation of Pharmaceutical Wholesalers (IFPW) This link will open in a new window to support the Strategic Training for Executive Program (STEP), an immersion apprenticeship program that aims to help strengthen the skills and experience of in-country EPI personnel who are managing vaccine cold chain equipment and infrastructure.
After a joint workshop with the International Coalition of Medicines Regulatory Authorities (ICMRA), the pharmaceutical industry outlines priority recommendations This link will open in a new window to enable vaccine manufacturing capacity.
UNICEF calls out restrictions on the export of syringes This link will open in a new window due to nationalism and predicts a shortage of auto-disable syringes for 2022.
Global COVID-19 deaths surpass 5 million. Approximately 4 billion people This link will open in a new window worldwide have received at least one dose of a COVID-19 vaccine.
Novavax announces submission of its COVID-19 vaccine for WHO authorization This link will open in a new window, a prerequisite to export the vaccine to countries participating in the COVAX Facility.
Pfizer's COVID-19 antiviral treatment This link will open in a new window is found to reduce risk of hospitalization or death.
Pfizer and the Medicines Patent Pool (MPP) sign a licensing agreement This link will open in a new window to supply 53% of the world's population with Pfizer's COVID-19 antiviral candidate treatment.
COVAX reaches 500 million deliveries This link will open in a new window of COVID-19 vaccines.
South Africa reports the detection of a new variant This link will open in a new window of COVID-19 to the WHO. Two days later, the WHO classifies the Omicron variant as a variant of concern..
Moderna announces new supply agreement to provide COVAX This link will open in a new window with an additional 150 million vaccine doses in 2022.
MSD and Ridgeback announce This link will open in a new window that their antiviral COVID-19 treatment significantly reduces the risk of hospitalization or death in high risk, unvaccinated adults with COVID-19.